Merck Says Organon To Acquire Alydia Health

By Michael Dabaie

Merck & Co. Inc. said that after the intended Merck spinoff of Organon, Organon will acquire Alydia Health.

Alydia Health is a commercial-stage medical device company focused on preventing maternal morbidity and mortality caused by postpartum hemorrhage or abnormal postpartum uterine bleeding.

Organon will be a global healthcare company formed through a spinoff from Merck to focus on women's health.

Organon agreed to acquire Alydia Health for up to $240 million total consideration, including $215 million upfront plus a $25 million contingent milestone payment.

Of the upfront payment, $50 million will be paid prior to the spinoff of Organon, $165 million will be paid by Organon upon the close of the acquisition, and the remainder will be paid by Organon upon achievement of the milestone.

Closing will be subject to completion of the spinoff of Organon from Merck, currently anticipated late in the second quarter of 2021.

Write to Michael Dabaie at [e-mail]

(END) Dow Jones Newswires

March 30, 2021 08:05 ET (12:05 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.